Pfizer Inc (PFE)

34.17
0.11 0.32
NYSE : Health Care
Prev Close 34.06
Open 34.08
Day Low/High 33.97 / 34.22
52 Wk Low/High 29.83 / 37.39
Volume 29.28M
Avg Volume 21.50M
Exchange NYSE
Shares Outstanding 5.97B
Market Cap 202.19B
EPS 1.20
P/E Ratio 28.47
Div & Yield 1.28 (3.80%)

Latest News

Biotech Movers: Regeneron Slides Back After Big Gains

Biotech Movers: Regeneron Slides Back After Big Gains

The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.

Pfizer Declares 32-Cent Third-Quarter 2017 Dividend

The board of directors of Pfizer Inc. today declared a 32-cent third-quarter 2017 dividend on the company's common stock, payable September 1, 2017, to shareholders of record at the close of business on August 4, 2017.

FDA Commisoner Takes on Big Pharma

FDA Commisoner Takes on Big Pharma

Investors should watch these companies come July 18th.

Will Pfizer Reexamine a Sale of its Consumer Division?

Will Pfizer Reexamine a Sale of its Consumer Division?

Morgan Stanley analyst David Risinger argued for the drugmaker to part ways with its consumer health division.

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Pfizer Firing on All Cylinders

Pfizer Firing on All Cylinders

Shares of Pfizer are moving well again Tuesday as the stock gains momentum following Monday's trendline break.

Pfizer Invites Public To View And Listen To Webcast Of August 1 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Pfizer Begins Phase 1 Clinical Trial To Evaluate Investigational Group B Streptococcus Vaccine

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection.

Pfizer Announces Results From XELJANZ® (tofacitinib Citrate) ORAL Strategy Study Published In The Lancet And Presented At The EULAR Annual Congress

Pfizer Inc. (NYSE:PFE) announced today detailed results from ORAL Strategy, a head-to-head, noninferiority Phase 3b/4 study of XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) as monotherapy or in combination...

Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug

Pfizer, Eli Lilly Granted Accelerated Review for Non-Opiod Pain Relief Drug

The FDA approval comes amidst America's struggle with an opioid epidemic.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Nearly One In Four New And Expectant Parents Have Never Heard Of Invasive Pneumococcal Disease According To A New Survey

Pfizer Inc. (NYSE:PFE), in partnership with Parents magazine (NYSE:MDP), announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious...

Pfizer And Lilly Receive FDA Fast Track Designation For Tanezumab

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.

Merck And Pfizer Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint In Two Phase 3 Studies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.

Prostate Cancer Drug Sales Drop as Feds Investigate Charities

Prostate Cancer Drug Sales Drop as Feds Investigate Charities

Prostate cancer drug sales have dropped during a federal investigation of charities that support the industry.

Astellas And Pfizer Announce Amendment To Clinical Research Protocol For Phase 3 PROSPER Trial Of Enzalutamide In Patients With Non-metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Pfizer Inc.

Advanced Trade: Pfizer

Advanced Trade: Pfizer

This tactic for PFE is a rare setup for those bullish in any underlying stock.

Amgen Wants to Boost Label on Powerhouse Repatha

Amgen Wants to Boost Label on Powerhouse Repatha

The day before Amgen appeared in court, the biopharma giant announced a submission to change its label on powerhouse drug Repatha.

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Goldman Sachs 38 th Annual Global Healthcare...

Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency

Companies also Announce Phase 1/2 Clinical Trial Evaluating SB-525 in Adults with Severe Hemophilia A is Now Open for Enrollment

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

Cramer: 15 Stocks to Buy for the Triathlon of Fear Coming on Super-Thursday

The handwringers will be out in full force. Their fear creates buying opportunities.

Johnson & Johnson's New Prostate Cancer Drug Might Make Pfizer Sick

Johnson & Johnson's New Prostate Cancer Drug Might Make Pfizer Sick

The companies are competing for approval for drugs that treat prostate cancer, the second most common cancer in men.

Pfizer Receives FDA Fast Track Designation For Tafamidis For Transthyretin Cardiomyopathy

Pfizer Inc. (NYSE:PFE) announced today that the U.

How to Use Technical Analysis to Make Money: Cramer's 'Mad Money' Recap (Monday 6/5/17)

How to Use Technical Analysis to Make Money: Cramer's 'Mad Money' Recap (Monday 6/5/17)

Why study charts? Because charts are like the footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

Pfizer Presents Final Phase 2 Data On Investigational PARP Inhibitor Talazoparib In Patients With Germline BRCA-Positive Advanced Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced Phase 2 data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline...